GlaxoSmithKline could be on the acquisition trail in the US, according to City traders.
Shares in US group Pacific Biosciences are 1.6% higher after speculation it could be the target of a $1.5bn bid, with GlaxoSmithKline and Roche among those mentioned as possible predators.
GlaxoSmithKline shares closed down 3p at 1444.5p. Earlier the company announced plans to file a key product for US approval earlier than expected. It said that following discussions with the US Food and Drug Administration, it would seek approval for a three-in-one inhaler for patients with chronic obstructive pulmonary disease by the end of 2016. It plans to file for European approval around the same time.
